Aptose Biosciences Inc. (APTOF)
OTCMKTS · Delayed Price · Currency is USD
2.660
+0.650 (32.34%)
Apr 3, 2025, 9:30 AM EST

Aptose Biosciences Company Description

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States.

The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin’s lymphomas, as well as relapsed or refractory acute myeloid leukemia.

It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib.

The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014.

Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Aptose Biosciences Inc.
Aptose Biosciences logo
Country Canada
Founded 1986
Industry Other
Employees 36
CEO William Rice

Contact Details

Address:
251 Consumers Road
Toronto, Ontario M2J 4R3
Canada
Phone 647 479 9828
Website aptose.com

Stock Details

Ticker Symbol APTOF
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
SIC Code 2836

Key Executives

Name Position
William Rice Chief Executive Officer
Fletcher Payne Chief Financial Officer